moneyheap
HALO · Analysis updated Nov 6, 2026, 11:45 AM ET
Why is Halozyme Therapeutics, Inc. (HALO) stock moving?
Halozyme reported a strong Q3: revenue rose 39% to $493M, royalties rose 44% to a record $341M, and adjusted EBITDA reached $336.2M. Management raised 2026 guidance on every metric, with revenue now $1.86B-$1.925B and non-GAAP EPS $8.75-$9.05. The market focused on the size of the raise instead. Guidance midpoints were only marginally above consensus, and the stock had risen about 12% in the month before the report, near its $134 high on Oct 30. Shares fell 5.7% on Nov 5 to $122.96, with volume well above average. They then fell a further 13% or so on Nov 6 to about $105 after a Leerink downgrade citing marginal upside. Citizens JMP raised its target to $149 and kept an outperform rating. Fundamentals remain strong, with a growing royalty base from VYVGART, Ocrevus Zunovo and other partner products. A Dutch patent win against Merck is a positive, but US litigation continues. Net leverage of 2.4x after the $1.5B convertible offering is a watch item. The near-term setback looks driven by expectations and positioning, not a deterioration in the business.
News behind the analysis
- Halozyme Therapeutics Reports Q3 2026 Earnings: Revenue of $493M and GAAP EPS of $2.01 Exceed EstimatesQ3 revenue rose 39% to $493M. GAAP EPS was $2.01 and non-GAAP EPS was $2.39, both above estimates.
- What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings CallManagement raised 2026 revenue, royalty, adjusted EBITDA and EPS guidance. Royalty growth was the main driver.
- Halozyme (HALO) Q3 2026 Earnings Call TranscriptRoyalties rose 44% to a record. VYVGART royalties rose 89% to $88.1M. Guidance was raised across the board.
- Halozyme falls 6% as raised guidance fails to impress investorsShares fell about 6% after hours. The raised guidance did not meet elevated expectations. The article also notes a Dutch court injunction against Merck's Keytruda Qlex launch in Europe.
- Halozyme stock dips as Leerink downgrades on Q3Leerink Partners downgraded the stock, citing only marginal upside in Q3 results. Shares fell more than 13% on Friday.
- Halozyme Therapeutics Stock Price Expected to Rise, Citizens JMP Analyst SaysCitizens JMP raised its price target from $93 to $149 with a market outperform rating. Shares still fell $17.74 to $105.22 in Friday trading.
- Halozyme Therapeutics Q3 In Line, Guidance Midpoint Below Consensus, Shares Fall After HoursResults were in line with estimates. Raised guidance midpoints lagged consensus after a roughly 11.9% gain over the prior month.
- Halozyme surprises with Q3 2026 sales but stock dropsRevenue and adjusted EPS beat consensus by 1.3% and 1.5%. Adjusted EBITDA of $336.2M beat by 3.2%. Guidance was lifted modestly.
- Premarket movers: Airbnb, Cloudflare, IREN rally; Atlassian, Five9 tumbleHalozyme fell 8.1% premarket. Investors wanted a bigger guidance upgrade, and the new midpoints were only marginally above Street expectations.
- Halozyme Therapeutics Q3 2026 Earnings Call Highlights: Record Revenue, Raised GuidanceHighlights include a Dutch patent win against Merck and $1.5B in convertible notes. US litigation with Merck continues, and net leverage is 2.4x.